Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, with or without a PD-1 inhibitor. Patients with “moderately” or “well” differentiated tumors showed a higher rate of dis
June 22, 2020
· 6 min read